1 mL BAC
10 units
resulting U-100 draw
- Concentration
- 20 mg/mL
- BAC added
- 1 mL
SinglePreclinicalPreclinicalVery Low confidenceSourced
Cartalax
A short peptide bioregulator marketed for cartilage-related claims. Internationally indexed controlled human evidence is too sparse to establish a protocol.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
Community-provenance subcutaneous bioregulator dosing from an authenticated research forum, about 1-2 mg once daily in roughly 20-day cycles, with some reports titrating to 5 mg. Forum reports only, not a validated schedule.
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.
Reported cycle phases
Select a point for its calculation examples- 20-day cycle2 mgReports cluster around 1-2 mg once daily over ~20-day cycles, about 3-4 cycles a year with ~2-month breaks; some inject locally near the joint.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 2 mg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
2 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw20 U
20-30 U reference band
2 mL BAC
20 units
resulting U-100 draw
- Concentration
- 10 mg/mL
- BAC added
- 2 mL
Shown in the diagram. Closest of these examples to 25 units.
3 mL BAC
30 units
resulting U-100 draw
- Concentration
- 6.667 mg/mL
- BAC added
- 3 mL
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational bioregulator schedule
2 mg daily in weeks 1-2, 3 mg in weeks 3-4, 4 mg in weeks 5-8 and 5 mg in weeks 9-12
The guide itself notes the absence of a matched human randomised dose-finding programme. These are retail educational conventions, not validated posology.
View sourceCommunity GuideOral, subcutaneous or intramuscular in reportsDaily or three times daily depending on source
online research community bioregulator channel
The spotlight states 20-40 mg orally for 10-20 days or 0.1 mg subcutaneously or intramuscularly three times daily for one month
Later community reports instead cluster around 1-2 mg daily for roughly 20-30 days, with still higher outliers. The archive does not reconcile the order-of-magnitude conflict; raw/bioregulators/bio-cartalax.md:22-24 and 257-280.
View sourceCommunity GuideSubcutaneousOnce daily in roughly 20-day cycles
authenticated research-forum (Peppys) reports
Subcutaneous reports cluster around 1-2 mg once daily in roughly 20-day cycles (some 30-40 days), with about 2-month breaks and 3-4 cycles a year; several researchers titrate to 3-5 mg daily, injections are often placed locally near the affected joint, and it is sold mainly as 20 mg vials
Forum provenance from an authenticated archive with usernames omitted. Reported outcomes are mixed and confounded because it is almost always stacked with ARA-290, KPV, BPC-157 or TB-500; the subcutaneous route dominates with an oral capsule form noted separately, and quantities are not interconverted between routes.
View sourceEvidence summary
A short peptide bioregulator marketed for cartilage-related claims. Internationally indexed controlled human evidence is too sparse to establish a protocol.
Protocol basis
The page records the evidence search and absence of a reproducible indexed human schedule rather than filling the gap with vendor conventions.
Community provenance (Peppys)
An authenticated research-forum archive records subcutaneous Cartalax around 1-2 mg once daily in roughly 20-day cycles, with about two-month breaks and three to four cycles a year; several reports titrate to 3-5 mg daily and many inject locally near the affected joint. Outcomes are mixed and hard to isolate because it is almost always stacked with ARA-290, KPV, BPC-157 or TB-500, and it is sold mainly as 20 mg vials with an oral capsule form noted separately. The archive does not reconcile this sub-milligram-to-5 mg spread with older channel figures that cited far higher oral or divided quantities. Usernames are omitted and the planner above reproduces the arithmetic of the reported quantities rather than validating them.
What remains uncertain
Human pharmacokinetics, controlled efficacy, adverse-event frequency and a validated formulation remain unknown.
Warnings and contraindications
No adequate controlled human regimen was identified in major indexed literature.
Brand or bioregulator claims are not substitutes for clinical outcomes.
Identity, formulation and route-specific safety require independent verification.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.